PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565678
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565678
The Pleurodynia Treatment Market size was valued at USD 130.90 Million in 2023, expanding at a CAGR of 5.90% from 2024 to 2032.
Pleurodynia is a condition characterized by sharp, stabbing pain in the chest due to inflammation of the pleura, the membrane surrounding the lungs. It often results from viral infections, such as those caused by the Coxsackievirus. Treatment typically focuses on relieving pain and addressing the underlying cause. Over-the-counter pain relievers like ibuprofen or acetaminophen are commonly used, alongside rest and sometimes corticosteroids for more severe cases. The market for pleurodynia treatment includes pharmaceutical companies developing pain management medications and diagnostic tools, as well as healthcare providers offering tailored treatment plans.
Pleurodynia Treatment Market- Market Dynamics
Rising incidence of pleurodynia cases due to increased viral infections.
Pleurodynia, often caused by viral infections such as coxsackievirus, has seen a rise in cases due to an increase in viral infections. This trend is reflected in the Pleurodynia Treatment market, which is growing as more cases are diagnosed and managed. Viral infections, particularly those prevalent in colder seasons, contribute to the increased incidence of pleurodynia.
The World Health Organization (WHO) provides relevant data through its Global Health Estimates. According to their 2021 report, viral infections, including those causing pleurodynia, have seen a significant increase over the past decade. Specifically, the incidence of viral infections causing respiratory symptoms, including pleurodynia, rose by approximately 20% between 2010 and 2020. This rise in cases emphasizes the growing need for effective treatments and interventions, driving the pleurodynia treatment market's expansion.
Pleurodynia Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)
Based on Diagnosis type segmentation, Blood tests was predicted to show maximum market share in the year 2023
Based on Treatment segmentation, Analgesics, and pain killers was the leading type in 2023
Based on Mode of Administration segmentation, Oral Medicines was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Pleurodynia Treatment Market is segmented on the basis of Diagnosis, Treatment, Mode of Administration, End-User, and Region.
The market is divided into three categories based on Diagnosis type Blood test, culture test, and X-ray. In the pleurodynia treatment market, blood tests are the most significant diagnostic segment. This prominence is due to their ability to identify underlying viral or bacterial infections that commonly cause pleurodynia. Blood tests can reveal markers of inflammation and infection, which are crucial for diagnosing and differentiating pleurodynia from other similar conditions. While culture tests and X-rays are also used, blood tests provide more immediate and actionable insights, making them central to the diagnostic process and guiding appropriate treatment strategies.
The market is divided into two categories based on Treatment Analgesics or Painkillers Immunoglobulin In the pleurodynia treatment market, analgesics or painkillers are the most significant treatment segment. This prominence stems from their primary role in managing the severe pain associated with pleurodynia, which is essential for patient relief and quality of life. Analgesics address the acute discomfort effectively, allowing patients to recover more comfortably. While immunoglobulins may be used to target underlying viral causes, analgesics are more widely utilized and directly address the symptom that most affects patients, making them the dominant treatment option.
Pleurodynia Treatment Market- Geographical Insights
In North America, the pleurodynia treatment market is experiencing notable growth due to increasing awareness and advancements in medicine. The prevalence of viral infections, which are a common cause of pleurodynia, is driving demand for effective treatments. The United States and Canada lead the market, with a high focus on research and development to enhance treatment options. The presence of established healthcare infrastructure and the rise in healthcare expenditure contribute to market expansion. Moreover, the growing geriatric population, which is more susceptible to such conditions, further fuels market growth. Despite this, challenges such as high treatment costs and the need for more comprehensive clinical studies on treatment efficacy remain.
The competitive landscape of the pleurodynia treatment market is characterized by the presence of several key players who are actively involved in the development and commercialization of therapies. Major pharmaceutical companies like Novartis Pharmaceuticals Corporation, Pfizer Inc., and GlaxoSmithKline plc are prominent in this space, leveraging their extensive research capabilities and market reach. Boehringer Ingelheim GmbH and AstraZeneca plc are also significant contributors, focusing on innovative treatment solutions and expanding their Diagnosis portfolios. Merck & Co., Inc. and Johnson & Johnson are key players that bring robust therapeutic options to the market. Additionally, companies such as Eli Lilly and Company, Sanofi, and AbbVie Inc. are notable for their contributions to the development of new treatments and strategic market positioning. These companies drive competition through ongoing research, clinical trials, and the introduction of novel therapies, aiming to address the unmet needs of patients with pleurodynia.
In January 2023, in an article on verywellhealth, an online award-winning resource that offers reliable and factual information on a range of health-related topics, patients can manage their pleurodynia-related pain with nonsteroidal anti-inflammatory drugs such as ibuprofen (Advil), even though there isn't a specific treatment for the condition. Additionally, they proposed that applying warm packs to the afflicted area might also aid in pain relief.